Following the 2026 US midterm elections, Democrats are putting healthcare affordability, drug pricing and insurance coverage at the centre of their agenda. Speaking at HLTH USA in Las Vegas, Senator ...
The main recipients of this fund will be European life sciences companies, though some across the US and other geographies will also benefit.
The US FDA has declined to approve Summit Therapeutics’ BLA for ivonescimab in patients with locally advanced or metastatic NSCLC.
The US Food and Drug Administration (FDA) appears to have quietly paused the Commissioner’s National Priority Voucher (CNPV) pilot programme, a controversial expedited review framework established by ...
The attending members of the editorial team talk through the key themes and takeaways from the 2026 BIO-Europe conference.
Omniose is developing a bioconjugate platform to create vaccines against multidrug resistant superbugs as anti-microbial resistance rises.
The US FDA has approved AstraZeneca's Imfinzi in combination with enfortumab vedotin for adult patients with MIBC who cannot receive or have refused cisplatin-based chemotherapy.
CRL has signed definitive agreements to acquire Frontage’s bioanalysis and DMPK operations in Exton, Pennsylvania for roughly $470m in cash.
Takeda has commercially launched Orzeyful (oveporexton) in the US as a prescription treatment for adult patients with narcolepsy type 1.
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have granted paediatric clinical trial waivers to Shanton Pharma for its lead candidate SAP-001, easing the drug’s ...
Delix Therapeutics has secured $100m in an oversubscribed Series C financing round to fund the development of Zalsupindole, an orally bioavailable neuroplastogen.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results